The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today recommended the two-dose Novavax COVID-19 vaccine as a COVID-19 vaccine primary series for emergency use in adults. If the CDC endorses ACIP’s recommendation, the protein-based vaccine would offer an option to individuals who may have an allergic reaction to or prefer not to receive an mRNA vaccine. The FDA last week authorized the vaccine for individuals age 18 and older. The departments of Health and Human Services and Defense this month secured 3.2 million doses of the vaccine to give states, federal pharmacy partners and federally qualified health centers. The vaccine can be stored at 2-8 degrees Celsius (about 36-46 degrees Fahrenheit), enabling the use of existing vaccine supply and cold chain channels.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday recommended clinicians test all sexually active patients with monkeypox symptoms for HIV and other…
Perspective
With fall in full swing, there are two easy steps that individuals can take to protect themselves and their families against illness — get a flu shot and get a…
Headline
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for…
Headline
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for…
Headline
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and…
Headline
AHA is continuing its annual work to help hospitals and health systems encourage their communities to stay healthy and protect themselves against the flu and…